We are live on ! Find out more
PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
+6.61%
1 Year Est. Return
+251.12%
3 Year Est. Return
+670.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$502M
AUM Growth
+$123M
Cap. Flow
+$124M
Cap. Flow %
24.65%
Top 10 Hldgs %
77.67%
Holding
30
New
5
Increased
16
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$35.7M
2
ARGX icon
argenx
ARGX
+$28.6M
3
INCY icon
Incyte
INCY
+$24.4M
4
BCYC
Bicycle Therapeutics
BCYC
+$22.1M
5
UTHR icon
United Therapeutics
UTHR
+$17.8M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$15.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$15.1M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$14.3M
4
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$13.3M
5
PRTA icon
Prothena Corp
PRTA
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
1
Legend Biotech
LEGN
$4.3B
$53.8M 10.73%
978,596
+146,868
+18% +$6.2M
GBT
2
DELISTED
Global Blood Therapeutics, Inc.
GBT
$46.2M 9.21%
1,445,566
+478,739
+50% +$14M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$44.3M 8.83%
659,968
+561,585
+571% +$35.7M
SRRA
4
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$44.1M 8.79%
801,314
+30,000
+4% +$1.57M
INCY icon
5
Incyte
INCY
$23.5B
$42.2M 8.42%
556,043
+321,624
+137% +$24.4M
ASND icon
6
Ascendis Pharma A/S
ASND
$16.7B
$40.2M 8.01%
432,170
+110,549
+34% +$10.4M
UTHR icon
7
United Therapeutics
UTHR
$26.3B
$38.4M 7.66%
163,066
+87,431
+116% +$17.8M
ARGX icon
8
argenx
ARGX
$57.4B
$33.7M 6.71%
+88,816
New +$28.6M
IMCR icon
9
Immunocore
IMCR
$1.78B
$24.9M 4.97%
667,417
+168,227
+34% +$5.46M
ARVN icon
10
Arvinas
ARVN
$518M
$21.8M 4.34%
517,406
+26,073
+5% +$1.31M
BCYC
11
Bicycle Therapeutics
BCYC
$270M
$17.6M 3.51%
+1,048,516
New +$22.1M
SNDX icon
12
Syndax Pharmaceuticals
SNDX
$1.84B
$16.9M 3.36%
876,156
+174,800
+25% +$2.91M
VRDN icon
13
Viridian Therapeutics
VRDN
$2.13B
$15.1M 3.01%
1,306,569
+50,518
+4% +$679K
MRUS
14
DELISTED
Merus
MRUS
$10.2M 2.04%
452,244
+202,506
+81% +$4.23M
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
$8.96M 1.79%
1,408,050
+250,804
+22% +$1.42M
TGTX icon
16
TG Therapeutics
TGTX
$8.58B
$8.35M 1.66%
+1,964,709
New +$12.3M
ALPN
17
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.04M 1.4%
826,779
+490,550
+146% +$4.23M
ENTA icon
18
Enanta Pharmaceuticals
ENTA
$372M
$7.01M 1.4%
+148,216
New +$8.04M
VOR icon
19
Vor Biopharma
VOR
$1.04B
$6.48M 1.29%
65,215
+20,495
+46% +$2.1M
OYST
20
DELISTED
Oyster Point Pharma, Inc. Common Stock
OYST
$5.77M 1.15%
1,333,330
+345,632
+35% +$1.96M
GRCL
21
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$4.31M 0.86%
783,445
– –
LQDA icon
22
Liquidia Corp
LQDA
$7.67B
$3.71M 0.74%
+850,961
New +$4.4M
CCCC icon
23
C4 Therapeutics
CCCC
$376M
$552K 0.11%
73,149
-426,347
-85% -$3.75M
FULC icon
24
Fulcrum Therapeutics
FULC
$248M
– –
-212,961
Closed -$5.04M
IOVA icon
25
Iovance Biotherapeutics
IOVA
$2.23B
– –
-907,428
Closed -$15.1M
1
2

Similar funds

KCM
Kensico Capital Management Greenwich, Connecticut $4.9B AUM 41.26% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FC
Freemont Capital Singapore $4.91B AUM 5.45% 1-Year Est. Return
WTC
WhitTier Trust Company Reno, Nevada $4.87B AUM 25.35% 1-Year Est. Return
MCM
Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return
MSRPS
Maryland State Retirement & Pension System Baltimore, Maryland $4.92B AUM 28.48% 1-Year Est. Return
MCCA
Mill Creek Capital Advisors Conshohocken, Pennsylvania $4.87B AUM 17.69% 1-Year Est. Return
SIA
Sit Investment Associates Minneapolis, Minnesota $4.93B AUM 12.22% 1-Year Est. Return

Paradigm Biocapital Advisors's Q2 2022 Portfolio in Review

As of Q2 2022, Paradigm Biocapital Advisors held 30 positions worth $502M, up 33% from $378M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Paradigm Biocapital Advisors deployed $124M of net new capital in Q2 2022, opening 5 new positions and adding to 16 existing holdings. Its largest new stake was argenx: 88,816 shares worth $33.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was C4 Therapeutics, an estimated $3.75M trimmed.

  • Paradigm Biocapital Advisors's largest Q2 2022 buy was argenx: 88,816 shares worth $33.7M.
  • Paradigm Biocapital Advisors added most to Mirati Therapeutics, Inc. Common Stock in Q2 2022, an estimated $35.7M increase.
  • Paradigm Biocapital Advisors's biggest Q2 2022 reduction was C4 Therapeutics, cutting an estimated $3.75M.
  • Paradigm Biocapital Advisors fully exited IVERIC bio, Inc. Common Stock in Q2 2022, selling an estimated $15.3M.
  • Paradigm Biocapital Advisors's ten largest holdings make up 78% of its $502M portfolio in Q2 2022.
  • Paradigm Biocapital Advisors opened 5 new positions and closed 7 in Q2 2022.
  • Paradigm Biocapital Advisors's portfolio value rose 33% quarter-over-quarter to $502M.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.